Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: Retrospective analysis of 58 prescription-event monitoring cohort studies

Pharmacoepidemiology and Drug Safety

Volumn 8, Issue 3, 1999, Pages 179-189

  Martin, Richard M ^a   Wilton, Lynda V ^a,b   Mann, Ronald D ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Asthma; Churg Strauss syndrome; Eosinophilia; Leukotriene receptor antagonists; Pharmacoepidemiology; Pharmacovigilance; Post marketing surveillance; Prescription event monitoring; Prevalence study; Vasculitis

Indexed keywords

ANTIASTHMATIC AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ARTICLE; CHURG STRAUSS SYNDROME; COHORT ANALYSIS; DATA BASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EOSINOPHILIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; VASCULITIS;

EID: 0033064873     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(199905/06)8:3<179::AID-PDS414>3.0.CO;2-K     Document Type: Article

References (27)

1. Lanham, J. G., Elkon, K. B., Pusey, C. D. and Hughes, G. R. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63: 65-81.
2. Rothenberg, M. E. Eosinophilia. N. Engl. J. Med. 1998; 338: 1592-1600.
3. Jennette, J. C. and Falk, R. J. Small-vessel vasculitis. N. Engl. J. Med. 1997; 337: 1512-1523.
4. Jennette, J. C., Falk, R. J., Andrassy, K. et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthr. Rheum. 1994; 37: 187-192.
5. Chumbly, L. C., Harrison, E. G. Jr and DeRemee, R. A. Allergic granulomatosis and angiitis (Churg-Strauss syndrome): report and analysis of 30 cases. Mayo Clin. Proc. 1977; 52: 477-484.
6. Watts, R. A. and Scott, D. G. I. Classification and epidemiology of the vasculitides. Balliere's Clin. Rheumatol. 1997; 11: 191-217.
7. Kurland, L. T., Chuang, T. Y. and Hunder, G. The epidemiology of systemic arthritis. In: The Epidemiology of the Rheumatic Diseases. Lawrence, R. C. and Shulman, L. P. (Eds), Gower, New York, 1984, pp. 196-205.
8. Churg, J. and Strauss, L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am. J. Pathol. 1951; 27: 277-301.
9. Masi, A. T., Hunder, G. G., Lie, J. T. et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthr. Rheum. 1990; 33: 1094-1100.
10. Kjellbo, H., Stakeberg, H. and Mellgren, J. Possibly thiazide-induced renal necrotizing vasculitis. Lancet 1965; 1: 1034-1035.
11. Jarzobski, J., Ferry, J., Wombolt, D., Fitch, D. M. and Egan, J. D. Vasculitis with allopurinol therapy. Am. Heart J. 1970; 79: 116-121.
12. Clarke, B. F., Cambell, I. W., Ewing, D. J., Beveridge, G. W. and MacDonald, M. K. Generalized hypersensitivity reaction and visceral arteritis with fatal outcome during glibenclamide therapy. Diabetes 1974; 23: 739-742.
13. Yermakov, V. M., Hitti, I. F. and Sutton, A. L. Necrotising vasculitis associated with diphenylhydrantoin: 2 fatal cases. Hum. Pathol. 1983; 14: 182-184.
14. Gaffey, C. M., Chun, B., Harvey, J. C. and Manz, H. J. Phenytoin-induced systemic granulomatous vasculitis. Arch. Pathol. Lab. Med. 1986; 110: 131-135.
15. Imai, H., Nakamoto, Y., Hirokawa, M., Akihama, T. and Miura, A. Carbamazepine-induced granulomatous necrotizing angiitis with acute renal failure. Nephron 1989; 51: 405-408.
16. Mathur, S., Dooley, J. and Scheuer, P. J. Quinine induced granulomatous hepatitis and vasculitis. Br. Med. J. 1990; 300: 613.
17. Morice, A. H., Kumwanda, J., Quereshi, N. and Curran, A. Mesalazine activation of eosinophil. Lancet 1997; 350: 1105.
18. Hubner, C., Dietz, A., Stremmel, W. et al. Macrolide-induced Churg-Strauss syndrome in a patient with atopy. Lancet 1997; 350: 563.
19. Wechsler, M. E., Garpestad, E., Flier, S. R. et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998; 279: 455-457.
20. Freemantle, S. N., Pearce, G. L., Wilton, L. V., Mackay, F. J. and Mann, R. D. The incidence of the most commonly reported events with 40 newly marketed drugs - a study by Prescription-Event Monitoring. Pharmacoepidemiol. Drug Saf. 1997; 6(Suppl. 1): S1-S8.
21. Mann, R. D., Wilton, L. V., Pearce, G. L., Mackay, F. J. and Dunn, N. R. Prescription-Event Monitoring in 1996 - a method of non-interventional observational cohort pharmacovigilance. Pharmacoepidemiol. Drug Saf. 1997; 6(Suppl. 3): S5-S11.
22. International Ethical Guidelines for Biomedical Research involving Human Subjects. CIOMS/WHO, Geneva, 1993.
23. Kirkwood, B. R. Essentials of Medical Statistics, Blackwell Science Ltd, Oxford, 1988, p. 109.
24. Gardner, M. J. Tables for calculation of confidence intervals: Table 3: Poisson distribution. In: Statistics with Confidence. Gardner, M. J. and Altman, D. G. (Eds), British Medical Journal, London, 1989, pp. 116-118.
25. StataCorp Stata Statistical Software: Release 5.0. College Station, TX: Stata Corporation, 1997.
26. Watts, R. A., Carruthers, D. M. and Scott, D. G. I. Epidemiology of systemic vasculitis: changing incidence or definition? Semin. Arthr. Rheumat. 1995; 25: 28-34.
27. McCormick, A., Fleming, D. and Charlton, J. Morbidity Statistics from General Practice. Fourth National Study 1991-1992. Series MBS No. 3. OPCS, London, 1995, p. 188.